Repurposing CD8 + T cell immunity against SARS-CoV-2 for cancer immunotherapy: a positive aspect of the COVID-19 pandemic?
Year: 2020
Type: article
Abstract: The COVID-19 pandemic has afflicted most countries on the planet. As a result, immunity against SARS-CoV-2, induced via natural infections or imminent vaccinations, is expected to develop in a large fraction of the global population. Here, we propose to exploit SARS-CoV-2-specific CD8+ T cells for cancer immunotherapy strategies.
Source: OncoImmunology
Institutions: Dalhousie University, Beatrice Hunter Cancer Research Institute, Inserm, Université Paris Cité, Institut Gustave Roussy, Sorbonne Université, Centre de Recherche des Cordeliers, La Ligue Contre le Cancer, Karolinska University Hospital, Institut Universitaire de France, Chinese Academy of Medical Sciences & Peking Union Medical College, Karolinska Institutet, Assistance Publique – Hôpitaux de Paris, Hôpital Européen Georges-Pompidou, Suzhou Institute of Systems Medicine
Language: English
Subfield: Immunology
Field: Immunology and Microbiology
Domain: Life Sciences
Open Access status: gold
Estimated APC paid: $1,431
Funders: Beatrice Hunter Cancer Research Institute, Dalhousie Medical Research Foundation, Agence Nationale de la Recherche, Ligue Contre le Cancer, Institut National Du Cancer, Chancellerie des Universités de Paris, European Research Area Network on Cardiovascular Diseases, Canadian Institutes of Health Research, High-end Foreign Experts Recruitment Plan of China
OpenAlex ID: W3043578946